Antifungal therapy in febrile neutropenic patients: Review of treatment choices and strategies for aspergillar infection

Supportive Care in Cancer

Volumn 15, Issue 2, 2007, Pages 137-141

  Klastersky, Jean ^a   Paesmans, Marianne ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Antifungal therapy; Aspergillus species; Empirical therapy; Febrile neutropenia; Preemptive therapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33847387497     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0137-3     Document Type: Review

References (28)

1. Martin GS, Mannino DM, Eaton S et al (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554
2. Winston DJ, Pranatharthi H, Chandrasekar H et al (1993) Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 118:495-503
3. Marr KA, Carter RA, Crippa F et al (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909-917
4. Wingard JR (2005) The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 17:89-92
5. Diekema DJ, Messer SA, Hollis RJ et al (2003) Activities of caspofungin, posaconazole, ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41:3623-3626
6. Marr KA, Crippa F, Leisenring W et al (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103:1527-1533
7. Winston DJ, Maziarz RT, Chandrasekar PH et al (2003) Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med 138: 705-713
8. Segal BH, Walsh TJ (2005) Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 173:707-717
9. Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415
10. Walsh TJ, Lee J, Dismukes WE (2002) Decisions about voriconazole versus liposomal amphotericin B. N Engl J Med 346:1499
11. Maertens J, Raad I, Petrikkos G et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563-1571
12. Walsh TJ, Patterson T, Longston A et al (2003) Posaconazole for treatment of invasive aspergillosis in patients who are refractory to an intolerant of conventional therapy: an externally controlled blinded trial. Blood 102:195-196
13. Candoni A, Mestroni R, Damiani D et al (2005) Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 75:227-233
14. Kontoyiannis DP, Lewis RE (2004) Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 126:165-175
15. Marr KA, Boeckh M, Carter RA et al (2004) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39:797-804
16. Pizzo PA, Robichaud KJ, Gill FA et al (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101-111
17. EORTC International Antimicrobial Therapy Cooperative Group (1989) Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86:668-672
18. Hugues WT, Armstrong D, Cornely OA et al (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-750
19. Walsh TJ, Finberg RW, Arndt C et al (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764-771
20. Walsh TJ, Pappas P, Winston DJ et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225-234
21. Walsh TJ, Teppler H, Donowitz GR et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402
22. Klastersky J (2004) Antifungal therapy in patients with fever and neutropenia - more rational and less empirical? N Engl J Med 351: 1445-1447
23. Guiot HFL, Fibbe WE, van't Wout (1994) Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 18:525-532
24. Corey L, Boeckh M (2002) Persistent fever in patients with neutropenia. N Engl J Med 346:222-224
25. Maertens J, Theunissen K, Verhoef G et al (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41:1242-1250
26. de Pauw BE (2005) Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 41:1251-1253
27. Ascioglu S, Rex H, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 37:7-14
28. Ming-Tsan L, His-Chi L, Woan-Ling C (2001) Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 33:1621-1627